Three Bridge Wealth Advisors LLC Sells 78 Shares of Becton, Dickinson and Company (NYSE:BDX)

Three Bridge Wealth Advisors LLC trimmed its stake in Becton, Dickinson and Company (NYSE:BDX) by 5.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,453 shares of the medical instruments supplier’s stock after selling 78 shares during the period. Three Bridge Wealth Advisors LLC’s holdings in Becton, Dickinson and Company were worth $330,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Livelsberger Financial Advisory purchased a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Becton, Dickinson and Company in the third quarter valued at $33,000. Tompkins Financial Corp lifted its holdings in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the last quarter. Kennebec Savings Bank purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth about $46,000. Finally, Versant Capital Management Inc grew its holdings in Becton, Dickinson and Company by 54.1% during the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 73 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BDX. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Piper Sandler raised their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $225.72 on Thursday. The company has a market capitalization of $65.46 billion, a P/E ratio of 37.50, a P/E/G ratio of 1.65 and a beta of 0.40. The company’s 50-day simple moving average is $232.36 and its two-hundred day simple moving average is $233.94. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.74.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.84%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Insider Activity

In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now directly owns 24,345 shares in the company, valued at $5,380,488.45. This represents a 15.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 2,838 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the sale, the executive vice president now owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. This represents a 31.61 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,544 shares of company stock worth $2,370,309. Company insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.